Myeloma

A 15-person team of multiple myeloma patients, doctors, family members, and supporters climbed the renowned 19,341-foot Uhuru Peak on Mount Kilimanjaro in Tanzania, Africa, in January, to raise awareness and funds for critical multiple myeloma research.

After losing her husband to myeloma, Novis Durie continued his project, the International Myeloma Foundation, which now has more than 200,000 members in 140 countries.

In an interview with CURE, Craig Hofmeister provided insight into the potential for combination regimens in relapsed/refractory patients with multiple myeloma.

"There are not a whole lot of patients that are able to do something like this, so we were doing it for them as well," says Chuck Wakefield. "It meant so much to them to have their names on the banner."

In an interview with CURE, Philippe Moreau discusses the significance of Ninlaro's approval and the TOURMALINE-MM1 study.

The approval was based on findings from the phase 3 ENDEAVOR trial.

CURE Media Group Employee Part of 15-Person Team of Multiple Myeloma Patients and Supporters.

The CD38 monoclonal antibody Darzalex demonstrated a 31 percent overall response rate as monotherapy for patients with heavily pretreated multiple myeloma.

An all orally administered regimen containing Ninlaro, Revlimid and dexamethasone showed a 5.9-month improvement in progression-free survival compared with Revlimid and dexamethasone alone.

On January 16, a 15-person team of multiple myeloma patients, doctors, family members and supporters will climb the famed Uhuru Peak on Mount Kilimanjaro.

Blake A. Morrison discusses the recent excitement in myeloma research.

The addition of the PD-1 inhibitor Keytruda (pembrolizumab) to an established multiple myeloma regimen elicited responses in 76 percent of 17 patients with relapsed/refractory disease.

In updated data from a phase 3 study, the addition of Empliciti reduced the risk of progression or death by 27 percent.

Genetically engineered T cells eradicated multiple myeloma cells in a single patient with advanced disease.

The approval was based on data from the phase 3 ELOQUENT-2 trial, in which adding Empliciti to standard Revlimid (lenalidomide)/dexamethasone reduced the risk of disease progression by 30 percent.

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.